Tisagenlecleucel in adult relapsed or refractory follicular lymphoma: the phase 2 ELARA trialNathan Fowler, Catherine Thiéblemont, Aiesha Zia et al.|Nature Medicine|2021Cited by 523
Addition of high-dose cytarabine to immunochemotherapy before autologous stem-cell transplantation in patients aged 65 years or younger with mantle cell lymphoma (MCL Younger): a randomised, open-label, phase 3 trial of the European Mantle Cell Lymphoma NetworkOlivier Hermine, Martin Dreyling, Eva Hoster et al.|The Lancet|2016Cited by 401
Confirmation of the Mantle-Cell Lymphoma International Prognostic Index in Randomized Trials of the European Mantle-Cell Lymphoma NetworkEva Hoster, Michael Unterhalt, Wolfgang Hiddemann et al.|Journal of Clinical Oncology|2014Cited by 164
High-dose cytarabine does not overcome the adverse prognostic value of CDKN2A and TP53 deletions in mantle cell lymphomaMarie‐Hélène Delfau‐Larue, Eva Hoster, Wolfgang Hiddemann et al.|Blood|2015Cited by 157
Treatment of Older Patients With Mantle Cell Lymphoma (MCL): Long-Term Follow-Up of the Randomized European MCL Elderly TrialHanneke C. Kluin‐Nelemans, Martin Dreyling, Eva Hoster et al.|Journal of Clinical Oncology|2019Cited by 143